Preventing Bone Loss During Androgen Deprivation Therapy for Prostate Cancer: Early Experience with Neridronate

Garnick, 1984, Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer, N Engl J Med, 311, 1281, 10.1056/NEJM198411153112004 1997, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial, Br J Urol, 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x Daniell, 2000, Progressive osteoporosis during androgen deprivation therapy for prostate cancer, J Urol, 163, 181, 10.1016/S0022-5347(05)68000-7 Smith, 2002, Osteoporosis during androgen deprivation therapy for prostate cancer, Urology, 60, 79, 10.1016/S0090-4295(02)01579-0 Hatano, 2000, Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer, BJU Int, 86, 449, 10.1046/j.1464-410X.2000.00774.x Melton, 2003, Fracture risk following bilateral orchiectomy, J Urol, 169, 1747, 10.1097/01.ju.0000059281.67667.97 Oefelein, 2001, Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer, J Urol, 166, 1724, 10.1016/S0022-5347(05)65661-3 Berruti, 2002, Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy, J Urol, 167, 2361, 10.1016/S0022-5347(05)64985-3 Hussain, 2003, Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation, BJU Int, 92, 690, 10.1046/j.1464-410X.2003.04471.x Smith, 2001, Low bone mineral density in hormone-naive men with prostate carcinoma, Cancer, 9, 2238, 10.1002/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2 Smith, 2002, Changes in body composition during androgen deprivation therapy for prostate cancer, J Clin Endocrinol Metab, 87, 599, 10.1210/jc.87.2.599 Chen, 2002, Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma, Cancer, 95, 2136, 10.1002/cncr.10967 Morote, 2003, Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment, Eur. Urol, 44, 661, 10.1016/S0302-2838(03)00379-8 Tyrrell, 2003, The non steroidal antiandrogen, bicalutamide (casodex), may preserve bone mineral density as compared with castration: results of a preliminary study, World J Urol, 21, 37, 10.1007/s00345-003-0322-7 Smith, 2001, Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer, N Engl J Med, 345, 948, 10.1056/NEJMoa010845 Smith, 2003, Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non metastatic prostate cancer, J Urol, 169, 2008, 10.1097/01.ju.0000063820.94994.95 Guise, 2004, Cancer treatment induce bone loss in prostate cancer: pathophysiology preclinical findings and treatment with zoledronic acid, Eur Urol, 46, 10.1016/j.eursup.2004.08.012 Orwoll, 2000, Alendronate for the treatment of osteoporosis in men, N Engl J Med, 343, 604, 10.1056/NEJM200008313430902 Delmas, 1987, Beneficial effects of aminohexane bisphosphonate in patients with Paget's disease of bone resistant to sodium etidronate, Am J Med, 83, 276, 10.1016/0002-9343(87)90699-1 Filipponi, 1998, Paget's disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate, Bone, 23, 543, 10.1016/S8756-3282(98)00133-1 Adami, 2002, Short-term intravenous therapy with Neridronate in Paget's disease, Clin Exp Rheumatol, 20, 55 O’Rourke, 1994, Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate), Br J Cancer, 69, 914, 10.1038/bjc.1994.176 Braga, 2003, Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis, Bone, 33, 342, 10.1016/S8756-3282(03)00084-X Adami, 2003, Intravenous neridronate in adults with osteogenesis imperfecta, J Bone Miner Res, 18, 126, 10.1359/jbmr.2003.18.1.126 Mittan, 2002, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs, J Clin Endocrinol Metab, 87, 3656, 10.1210/jc.87.8.3656 Preston, 2002, Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss, Prostate Cancer Prostatic Dis, 5, 304, 10.1038/sj.pcan.4500599 Saad, 2004, Role of Bisphosphonates in Prostate Cancer, Eur Urol, 45, 26, 10.1016/j.eururo.2003.10.003 Bae, 2004, The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate, J Urol., 172, 2137, 10.1097/01.ju.0000141515.67372.e5 Cummings, 1990, Appendicular bone density and age predict hip fracture in women, JAMA, 263, 665, 10.1001/jama.263.5.665 Snyder, 1999, Effect of testosterone treatment on bone mineral density in men over 65 years of age, J Clin Endocrinol Metab, 84, 1966, 10.1210/jc.84.6.1966 Katznelson, 1996, Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism, J Clin Endocrinol Metab, 81, 4358, 10.1210/jc.81.12.4358 Finkelstein, 1989, Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism, J Clin Endocrinol Metab, 69, 776, 10.1210/jcem-69-4-776